Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets-Reference-Cited by-同舟云学术

Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets

Published:2014-03-31 Issue: Volume:5 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Robillard Nelly,WuillÃ¨me Soraya,Moreau Philippe,BÃ©nÃ© Marie C.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference25 articles.

1. Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?;Tatsas;Am J Clin Pathol,2010

2. Heterogeneity in the multiple myeloma tumor clone;Guikema;Leuk Lymphoma,2004

3. The phenotype of normal, reactive and malignant plasma cells. Identification of â€œmany and multiple myelomasâ€ and of new targets for myeloma therapy;Bataille;Haematologica,2006

4. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders;Raja;Br J Haematol,2010

5. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology;Cannizzo;Cytometry B Clin Cytom,2010

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma;Frontiers in Oncology;2024-08-08

2. Simple flow cytometry method using a myeloma panel that easily reveals clonal proliferation of mature B-cells;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-05

3. Successful treatment of refractory donor‐specific‐human leukocyte antigen‐antibody‐induced primary graft‐failure with daratumumab: A case report;eJHaem;2024-06-19

4. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy;Frontiers in Bioscience-Landmark;2024-06-17

5. CD56 expression predicts response to Daratumumab-based regimens;Blood Cancer Journal;2024-04-12